Fisher Asset Management
NRIX icon

Fisher Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Fisher Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.96M Sell
369,465
-15,366
-4% -$262K ﹤0.01% 423
2026
Q1 		$5.96M Buy
+384,831
New +$6.38M ﹤0.01% 449

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fisher Asset Management's NRIX Position: Q2 2026 in Review

Fisher Asset Management reduced its Nurix Therapeutics (NRIX) stake by 4% in Q2 2026, selling an estimated $262K and leaving 369,465 shares worth $8.96M. The position accounts for ﹤0.01% of the portfolio, ranked #423.

Fisher Asset Management first reported a position in NRIX in Q1 2026 and has held it in 2 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Fisher Asset Management held 369,465 shares of Nurix Therapeutics worth $8.96M as of Q2 2026.
  • Fisher Asset Management sold 15,366 Nurix Therapeutics shares in Q2 2026, an estimated $262K.
  • Nurix Therapeutics made up ﹤0.01% of Fisher Asset Management's portfolio in Q2 2026, its #423 holding.
  • Fisher Asset Management first reported a position in Nurix Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.